Clinical Trials

Penn Abramson huCART-meso Phase 1 (NCT03054298; PMID 41566776) — fully human mesothelin CAR-T; 35% CRS, 60% stable disease, 2+ year T-cell persistence.

Stage 3 pleural mesothelioma survival data broken down by cell type, treatment, and prognostic factors. Median OS 15-19 months with surgery; 14% 5-year survival with immunotherapy. 5 treatment paths explained for 2026.

Learn how surgical volume, NCI designation, and published outcomes data help mesothelioma patients choose the right treatment center. Evidence-based evaluation framework for 2026.

Defactinib (VS-6063) FAK inhibitor showed HR 0.56 in merlin-low mesothelioma patients. Learn about COMMAND trial results, biomarkers, and combination trials.

Johns Hopkins Kimmel Cancer Center's perioperative immunotherapy trials show 80% surgical completion and extended survival for mesothelioma patients. Learn who qualifies.

CRS-HIPEC (cytoreductive surgery + hyperthermic chemotherapy) achieves 53-month median survival and 47% five-year survival for peritoneal mesothelioma patients. Learn candidacy, outcomes, and leading treatment centers.

NCI awards $10.7M to Penn for CAR T-cell therapy targeting mesothelin in mesothelioma. Explore clinical data, eligibility, and breakthrough cell immunotherapy.

Phase 3 ATOMIC-Meso trial results show pegargiminase (ADI-PEG20) quadrupled 3-year survival rates in mesothelioma. Learn how arginine deprivation therapy works, eligibility, and access to this breakthrough treatment.

VT3989 shows 32% response rate and 86% disease control in refractory mesothelioma. Learn about this first-in-class TEAD inhibitor's path to FDA approval and clinical trial access.

Mayo Clinic's #1-ranked mesothelioma program delivers multidisciplinary treatment with access to clinical trials across Rochester, Phoenix, and Jacksonville locations.

Compare EPP and P/D surgery for mesothelioma, understand survival rates, and learn about emerging surgical techniques. Expert guide to choosing the right procedure for your diagnosis.

Memorial Sloan Kettering Cancer Center offers pioneering mesothelioma surgery, immunotherapy, and clinical trials. Learn about MSK's treatment approach, specialists, and how to become a patient.

MD Anderson Cancer Center in Houston offers world-class mesothelioma treatment with pioneering surgical techniques and clinical trials. Learn what to expect and how to access care.

FDA-approved Opdivo + Yervoy now has 5-year data: 14% long-term survival vs 6% with chemo. Learn who qualifies for mesothelioma immunotherapy in 2026.

Explore the best mesothelioma treatment options in 2026, including 56+ active clinical trials, immunotherapy advances, and targeted therapies like pegargiminase that are improving survival rates.

These 6 specialized mesothelioma treatment centers offer access to expert surgeons, clinical trials, and significantly better postoperative outcomes than general hospitals. Learn what makes each center unique.